2,141
Participants
Start Date
February 27, 2007
Primary Completion Date
August 1, 2011
Study Completion Date
August 1, 2011
13-valent pneumococcal conjugate vaccine (13vPnC)
0.5 mL dose administered on day 1
23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
0.5 mL dose administered on day 1
13-valent pneumococcal conjugate vaccine (13vPnC)
0.5 mL dose administered on day 1
13-valent pneumococcal conjugate vaccine (13vPnC)
0.5 mL dose administered on day 1
13-valent pneumococcal conjugate vaccine (13vPnC)
0.5 mL dose administered 3-4 years after dose 1
23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
0.5 mL dose administered 3-4 years after dose 1
13-valent pneumococcal conjugate vaccine (13vPnC)
0.5 mL dose administered 3-4 years after dose 1
University of Rochester Medical Center, Rochester
Primary Physicians Research, Pittsburgh
Primary Physicians Research, Upper Saint Clair
PMG Research of Raleigh, LLC, Raleigh
University Clinical Research, Inc., Pembroke Pines
Accelovance, Huntsville
Internal Medicine and Pediatrics Associates of Bristol, PC, Bristol
PMG Research of Bristoll, LLC, Bristol
Kentucky Pediatric /Adult Research, Bardstown
University of Louisville, Louisville
Cincinnati Children's Hospital Medical Center, Cincinnati
Accelovance, South Bend
Radiant Research - St. Louis, St Louis
Center for Pharmaceutical Research, Kansas City
Heartland Research Associates LLC, Wichita
Heartland Research Associates, LLC, Wichita
Advanced Clinical Research, Meridian
Advanced Clinical Research, West Jordan
J. Lewis Research/First Med, West Jordan
J. Lewis Research Inc./Foothill Family Clinic South, Salt Lake City
J. Lewis Research Inc./Foothill Family Clinic South, Salt Lake City
Clinical Research Advantage/Central Phoenix, Phoenix
East Valley Family Physicians, PLC, Chandler
Group Health Research Institute, Seattle
PMG Research of Raleigh, LLC, Cary
Omega Medical Research, Warwick
Lead Sponsor
Pfizer
INDUSTRY